Shares of Petiq Inc (NASDAQ:PETQ) have earned a consensus recommendation of “Buy” from the six research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $27.00.

Several equities analysts have recently commented on PETQ shares. SunTrust Banks, Inc. assumed coverage on Petiq in a research note on Tuesday. They set a “buy” rating and a $28.00 price target on the stock. Jefferies Group LLC assumed coverage on Petiq in a research report on Tuesday. They set a “hold” rating and a $25.00 price objective on the stock. CIBC assumed coverage on Petiq in a research report on Tuesday. They set an “outperform” rating and a $28.00 price objective on the stock. Raymond James Financial, Inc. assumed coverage on Petiq in a research report on Tuesday. They set an “outperform” rating and a $26.00 price objective on the stock. Finally, Oppenheimer Holdings, Inc. assumed coverage on Petiq in a research report on Tuesday. They set an “outperform” rating and a $28.00 price objective on the stock.

Shares of Petiq (PETQ) traded down 0.66% during trading on Tuesday, reaching $22.72. 302,015 shares of the company were exchanged. The firm’s market capitalization is $279.12 million. Petiq has a 1-year low of $19.76 and a 1-year high of $25.44. The firm’s 50 day moving average is $28.29 and its 200 day moving average is $28.29.

TRADEMARK VIOLATION WARNING: This news story was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.watchlistnews.com/petiq-inc-petq-given-consensus-rating-of-buy-by-analysts/1492155.html.

Petiq Company Profile

PetIQ, Inc is engaged in manufacturing and distributing pet medication and health and wellness products to the retail channel in the United States. The Company provides retail stores with third-party brands, including Frontline Plus, Heartgard Plus, PetAction Plus, Advecta II, Pet Lock Plus, Pet Lock Max, TruProfen and Heartshield.

Analyst Recommendations for Petiq (NASDAQ:PETQ)

Receive News & Ratings for Petiq Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petiq Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.